Macular Degeneration Treatment Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Disease Indication (Dry Age-related macular degeneration treatment, Wet age-related macular de-generation treatment, Others); Drug Class (Anti-Vascular endothelial growth factor, Others); End User (Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals)
Report Code: TIPRE00004433 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Macular Degeneration is a medical condition that may result in blurred or no vision in the center of the visual field. There may be no symptoms at times at the beginning of macular degeneration, but eventually some people experience a gradual worsening of vision that may affect both or one eye.
MARKET DYNAMICS
The Macular Degeneration Treatment Market is anticipated to grow in the forecast period owing to driving factors such as increasing population of geriatric patients, rising patient population suffering from Macular Degeneration, growing awareness about drugs for treating AMD, introduction on new therapies, improving healthcare as well as healthcare infrastructure, and increase in prevalence and incidence of retinal disorders. Nevertheless, continuous pressure from some key players in binding the usage of different drugs for wet AMD and intrusive administration methods is expected to restrict the market growth during the forecast period.
MARKET SCOPE
The "Global Macular Degeneration Treatment Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Macular Degeneration Treatment Market with detailed market segmentation by Disease Indication, Drug Class, End User and geography. The global Macular Degeneration Treatment Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Macular Degeneration Treatment Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Macular Degeneration Treatment Market is segmented on the basis of Disease Indication, Drug Class and End User. Based on Disease Indication the market is segmented into Dry Age-related macular degeneration treatment, Wet age-related macular de-generation treatment and Others. Based on Drug Class the market is segmented into Anti-Vascular endothelial growth factor and Others. Based on End User the market is segmented into Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals.
Get more information on this report :
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Macular Degeneration Treatment Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Macular Degeneration Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Macular Degeneration Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Macular Degeneration Treatment Market in these regions.
Get more information on this report :
MARKET PLAYERS
The reports cover key developments in the Macular Degeneration Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Macular Degeneration Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for Macular Degeneration Treatment Market in the global market. Below mentioned is the list of few companies engaged in the Macular Degeneration Treatment Market.
The report also includes the profiles of key Macular Degeneration Treatment Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development In Past Five Years.
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Neurotech Pharmaceuticals, Inc
- Ophthotech Corporation
- F. Hoffmann-La Roche Ltd
- StemCells Inc
- Pfizer, Inc
- Sanofi
- Santen Pharmaceuticals
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Macular Degeneration Treatment Market - By Disease Indication
1.3.2 Macular Degeneration Treatment Market - By Drug Class
1.3.3 Macular Degeneration Treatment Market - By End User
1.3.4 Macular Degeneration Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. MACULAR DEGENERATION TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MACULAR DEGENERATION TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MACULAR DEGENERATION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET OVERVIEW
6.2. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
7.1. OVERVIEW
7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
7.3. DRY AGE-RELATED MACULAR DEGENERATION TREATMENT
7.3.1. Overview
7.3.2. Dry Age-related macular degeneration treatment Market Forecast and Analysis
7.4. WET AGE-RELATED MACULAR DE-GENERATION TREATMENT
7.4.1. Overview
7.4.2. Wet age-related macular de-generation treatment Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
8.3.1. Overview
8.3.2. Anti-Vascular endothelial growth factor Market Forecast and Analysis
8.4. OTHERS
8.4.1. Overview
8.4.2. Others Market Forecast and Analysis
9. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. AMBULATORY SURGICAL CENTERS
9.3.1. Overview
9.3.2. Ambulatory Surgical Centers Market Forecast and Analysis
9.4. OPHTHALMIC CLINICS
9.4.1. Overview
9.4.2. Ophthalmic Clinics Market Forecast and Analysis
9.5. HOSPITALS.
9.5.1. Overview
9.5.2. Hospitals. Market Forecast and Analysis
10. MACULAR DEGENERATION TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Macular Degeneration Treatment Market Overview
10.1.2 North America Macular Degeneration Treatment Market Forecasts and Analysis
10.1.3 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.1.4 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.1.5 North America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Macular Degeneration Treatment Market
10.1.6.1.1 United States Macular Degeneration Treatment Market by Disease Indication
10.1.6.1.2 United States Macular Degeneration Treatment Market by Drug Class
10.1.6.1.3 United States Macular Degeneration Treatment Market by End User
10.1.6.2 Canada Macular Degeneration Treatment Market
10.1.6.2.1 Canada Macular Degeneration Treatment Market by Disease Indication
10.1.6.2.2 Canada Macular Degeneration Treatment Market by Drug Class
10.1.6.2.3 Canada Macular Degeneration Treatment Market by End User
10.1.6.3 Mexico Macular Degeneration Treatment Market
10.1.6.3.1 Mexico Macular Degeneration Treatment Market by Disease Indication
10.1.6.3.2 Mexico Macular Degeneration Treatment Market by Drug Class
10.1.6.3.3 Mexico Macular Degeneration Treatment Market by End User
10.1.6.4 US Macular Degeneration Treatment Market
10.1.6.4.1 US Macular Degeneration Treatment Market by Disease Indication
10.1.6.4.2 US Macular Degeneration Treatment Market by Drug Class
10.1.6.4.3 US Macular Degeneration Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Macular Degeneration Treatment Market Overview
10.2.2 Europe Macular Degeneration Treatment Market Forecasts and Analysis
10.2.3 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.2.4 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Macular Degeneration Treatment Market
10.2.6.1.1 Germany Macular Degeneration Treatment Market by Disease Indication
10.2.6.1.2 Germany Macular Degeneration Treatment Market by Drug Class
10.2.6.1.3 Germany Macular Degeneration Treatment Market by End User
10.2.6.2 France Macular Degeneration Treatment Market
10.2.6.2.1 France Macular Degeneration Treatment Market by Disease Indication
10.2.6.2.2 France Macular Degeneration Treatment Market by Drug Class
10.2.6.2.3 France Macular Degeneration Treatment Market by End User
10.2.6.3 Italy Macular Degeneration Treatment Market
10.2.6.3.1 Italy Macular Degeneration Treatment Market by Disease Indication
10.2.6.3.2 Italy Macular Degeneration Treatment Market by Drug Class
10.2.6.3.3 Italy Macular Degeneration Treatment Market by End User
10.2.6.4 Spain Macular Degeneration Treatment Market
10.2.6.4.1 Spain Macular Degeneration Treatment Market by Disease Indication
10.2.6.4.2 Spain Macular Degeneration Treatment Market by Drug Class
10.2.6.4.3 Spain Macular Degeneration Treatment Market by End User
10.2.6.5 United Kingdom Macular Degeneration Treatment Market
10.2.6.5.1 United Kingdom Macular Degeneration Treatment Market by Disease Indication
10.2.6.5.2 United Kingdom Macular Degeneration Treatment Market by Drug Class
10.2.6.5.3 United Kingdom Macular Degeneration Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Macular Degeneration Treatment Market Overview
10.3.2 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.3.4 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Macular Degeneration Treatment Market
10.3.6.1.1 Australia Macular Degeneration Treatment Market by Disease Indication
10.3.6.1.2 Australia Macular Degeneration Treatment Market by Drug Class
10.3.6.1.3 Australia Macular Degeneration Treatment Market by End User
10.3.6.2 China Macular Degeneration Treatment Market
10.3.6.2.1 China Macular Degeneration Treatment Market by Disease Indication
10.3.6.2.2 China Macular Degeneration Treatment Market by Drug Class
10.3.6.2.3 China Macular Degeneration Treatment Market by End User
10.3.6.3 India Macular Degeneration Treatment Market
10.3.6.3.1 India Macular Degeneration Treatment Market by Disease Indication
10.3.6.3.2 India Macular Degeneration Treatment Market by Drug Class
10.3.6.3.3 India Macular Degeneration Treatment Market by End User
10.3.6.4 Japan Macular Degeneration Treatment Market
10.3.6.4.1 Japan Macular Degeneration Treatment Market by Disease Indication
10.3.6.4.2 Japan Macular Degeneration Treatment Market by Drug Class
10.3.6.4.3 Japan Macular Degeneration Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Macular Degeneration Treatment Market Overview
10.4.2 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.4.4 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Macular Degeneration Treatment Market
10.4.6.1.1 South Africa Macular Degeneration Treatment Market by Disease Indication
10.4.6.1.2 South Africa Macular Degeneration Treatment Market by Drug Class
10.4.6.1.3 South Africa Macular Degeneration Treatment Market by End User
10.4.6.2 Saudi Arabia Macular Degeneration Treatment Market
10.4.6.2.1 Saudi Arabia Macular Degeneration Treatment Market by Disease Indication
10.4.6.2.2 Saudi Arabia Macular Degeneration Treatment Market by Drug Class
10.4.6.2.3 Saudi Arabia Macular Degeneration Treatment Market by End User
10.4.6.3 U.A.E Macular Degeneration Treatment Market
10.4.6.3.1 U.A.E Macular Degeneration Treatment Market by Disease Indication
10.4.6.3.2 U.A.E Macular Degeneration Treatment Market by Drug Class
10.4.6.3.3 U.A.E Macular Degeneration Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Macular Degeneration Treatment Market Overview
10.5.2 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis
10.5.3 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.5.4 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Macular Degeneration Treatment Market
10.5.6.1.1 Brazil Macular Degeneration Treatment Market by Disease Indication
10.5.6.1.2 Brazil Macular Degeneration Treatment Market by Drug Class
10.5.6.1.3 Brazil Macular Degeneration Treatment Market by End User
10.5.6.2 Argentina Macular Degeneration Treatment Market
10.5.6.2.1 Argentina Macular Degeneration Treatment Market by Disease Indication
10.5.6.2.2 Argentina Macular Degeneration Treatment Market by Drug Class
10.5.6.2.3 Argentina Macular Degeneration Treatment Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MACULAR DEGENERATION TREATMENT MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BAYER AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. NEUROTECH PHARMACEUTICALS, INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. OPHTHOTECH CORPORATION
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. STEMCELLS INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. PFIZER, INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SANOFI
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANTEN PHARMACEUTICALS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Macular Degeneration Treatment Market - By Disease Indication
1.3.2 Macular Degeneration Treatment Market - By Drug Class
1.3.3 Macular Degeneration Treatment Market - By End User
1.3.4 Macular Degeneration Treatment Market - By Region
1.3.4.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. MACULAR DEGENERATION TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MACULAR DEGENERATION TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MACULAR DEGENERATION TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET OVERVIEW
6.2. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION
7.1. OVERVIEW
7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS
7.3. DRY AGE-RELATED MACULAR DEGENERATION TREATMENT
7.3.1. Overview
7.3.2. Dry Age-related macular degeneration treatment Market Forecast and Analysis
7.4. WET AGE-RELATED MACULAR DE-GENERATION TREATMENT
7.4.1. Overview
7.4.2. Wet age-related macular de-generation treatment Market Forecast and Analysis
7.5. OTHERS
7.5.1. Overview
7.5.2. Others Market Forecast and Analysis
8. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR
8.3.1. Overview
8.3.2. Anti-Vascular endothelial growth factor Market Forecast and Analysis
8.4. OTHERS
8.4.1. Overview
8.4.2. Others Market Forecast and Analysis
9. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. AMBULATORY SURGICAL CENTERS
9.3.1. Overview
9.3.2. Ambulatory Surgical Centers Market Forecast and Analysis
9.4. OPHTHALMIC CLINICS
9.4.1. Overview
9.4.2. Ophthalmic Clinics Market Forecast and Analysis
9.5. HOSPITALS.
9.5.1. Overview
9.5.2. Hospitals. Market Forecast and Analysis
10. MACULAR DEGENERATION TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Macular Degeneration Treatment Market Overview
10.1.2 North America Macular Degeneration Treatment Market Forecasts and Analysis
10.1.3 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.1.4 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.1.5 North America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.1.6 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.1.6.1 United States Macular Degeneration Treatment Market
10.1.6.1.1 United States Macular Degeneration Treatment Market by Disease Indication
10.1.6.1.2 United States Macular Degeneration Treatment Market by Drug Class
10.1.6.1.3 United States Macular Degeneration Treatment Market by End User
10.1.6.2 Canada Macular Degeneration Treatment Market
10.1.6.2.1 Canada Macular Degeneration Treatment Market by Disease Indication
10.1.6.2.2 Canada Macular Degeneration Treatment Market by Drug Class
10.1.6.2.3 Canada Macular Degeneration Treatment Market by End User
10.1.6.3 Mexico Macular Degeneration Treatment Market
10.1.6.3.1 Mexico Macular Degeneration Treatment Market by Disease Indication
10.1.6.3.2 Mexico Macular Degeneration Treatment Market by Drug Class
10.1.6.3.3 Mexico Macular Degeneration Treatment Market by End User
10.1.6.4 US Macular Degeneration Treatment Market
10.1.6.4.1 US Macular Degeneration Treatment Market by Disease Indication
10.1.6.4.2 US Macular Degeneration Treatment Market by Drug Class
10.1.6.4.3 US Macular Degeneration Treatment Market by End User
10.2. EUROPE
10.2.1 Europe Macular Degeneration Treatment Market Overview
10.2.2 Europe Macular Degeneration Treatment Market Forecasts and Analysis
10.2.3 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.2.4 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.2.5 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.2.6 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Macular Degeneration Treatment Market
10.2.6.1.1 Germany Macular Degeneration Treatment Market by Disease Indication
10.2.6.1.2 Germany Macular Degeneration Treatment Market by Drug Class
10.2.6.1.3 Germany Macular Degeneration Treatment Market by End User
10.2.6.2 France Macular Degeneration Treatment Market
10.2.6.2.1 France Macular Degeneration Treatment Market by Disease Indication
10.2.6.2.2 France Macular Degeneration Treatment Market by Drug Class
10.2.6.2.3 France Macular Degeneration Treatment Market by End User
10.2.6.3 Italy Macular Degeneration Treatment Market
10.2.6.3.1 Italy Macular Degeneration Treatment Market by Disease Indication
10.2.6.3.2 Italy Macular Degeneration Treatment Market by Drug Class
10.2.6.3.3 Italy Macular Degeneration Treatment Market by End User
10.2.6.4 Spain Macular Degeneration Treatment Market
10.2.6.4.1 Spain Macular Degeneration Treatment Market by Disease Indication
10.2.6.4.2 Spain Macular Degeneration Treatment Market by Drug Class
10.2.6.4.3 Spain Macular Degeneration Treatment Market by End User
10.2.6.5 United Kingdom Macular Degeneration Treatment Market
10.2.6.5.1 United Kingdom Macular Degeneration Treatment Market by Disease Indication
10.2.6.5.2 United Kingdom Macular Degeneration Treatment Market by Drug Class
10.2.6.5.3 United Kingdom Macular Degeneration Treatment Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Macular Degeneration Treatment Market Overview
10.3.2 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis
10.3.3 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.3.4 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.3.5 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Macular Degeneration Treatment Market
10.3.6.1.1 Australia Macular Degeneration Treatment Market by Disease Indication
10.3.6.1.2 Australia Macular Degeneration Treatment Market by Drug Class
10.3.6.1.3 Australia Macular Degeneration Treatment Market by End User
10.3.6.2 China Macular Degeneration Treatment Market
10.3.6.2.1 China Macular Degeneration Treatment Market by Disease Indication
10.3.6.2.2 China Macular Degeneration Treatment Market by Drug Class
10.3.6.2.3 China Macular Degeneration Treatment Market by End User
10.3.6.3 India Macular Degeneration Treatment Market
10.3.6.3.1 India Macular Degeneration Treatment Market by Disease Indication
10.3.6.3.2 India Macular Degeneration Treatment Market by Drug Class
10.3.6.3.3 India Macular Degeneration Treatment Market by End User
10.3.6.4 Japan Macular Degeneration Treatment Market
10.3.6.4.1 Japan Macular Degeneration Treatment Market by Disease Indication
10.3.6.4.2 Japan Macular Degeneration Treatment Market by Drug Class
10.3.6.4.3 Japan Macular Degeneration Treatment Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Macular Degeneration Treatment Market Overview
10.4.2 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis
10.4.3 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.4.4 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.4.5 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Macular Degeneration Treatment Market
10.4.6.1.1 South Africa Macular Degeneration Treatment Market by Disease Indication
10.4.6.1.2 South Africa Macular Degeneration Treatment Market by Drug Class
10.4.6.1.3 South Africa Macular Degeneration Treatment Market by End User
10.4.6.2 Saudi Arabia Macular Degeneration Treatment Market
10.4.6.2.1 Saudi Arabia Macular Degeneration Treatment Market by Disease Indication
10.4.6.2.2 Saudi Arabia Macular Degeneration Treatment Market by Drug Class
10.4.6.2.3 Saudi Arabia Macular Degeneration Treatment Market by End User
10.4.6.3 U.A.E Macular Degeneration Treatment Market
10.4.6.3.1 U.A.E Macular Degeneration Treatment Market by Disease Indication
10.4.6.3.2 U.A.E Macular Degeneration Treatment Market by Drug Class
10.4.6.3.3 U.A.E Macular Degeneration Treatment Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Macular Degeneration Treatment Market Overview
10.5.2 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis
10.5.3 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication
10.5.4 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class
10.5.5 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By End User
10.5.6 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Macular Degeneration Treatment Market
10.5.6.1.1 Brazil Macular Degeneration Treatment Market by Disease Indication
10.5.6.1.2 Brazil Macular Degeneration Treatment Market by Drug Class
10.5.6.1.3 Brazil Macular Degeneration Treatment Market by End User
10.5.6.2 Argentina Macular Degeneration Treatment Market
10.5.6.2.1 Argentina Macular Degeneration Treatment Market by Disease Indication
10.5.6.2.2 Argentina Macular Degeneration Treatment Market by Drug Class
10.5.6.2.3 Argentina Macular Degeneration Treatment Market by End User
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. MACULAR DEGENERATION TREATMENT MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BAYER AG
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. NEUROTECH PHARMACEUTICALS, INC
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. OPHTHOTECH CORPORATION
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. STEMCELLS INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. PFIZER, INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. SANOFI
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANTEN PHARMACEUTICALS
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Neurotech Pharmaceuticals, Inc
- Ophthotech Corporation
- F. Hoffmann-La Roche Ltd
- StemCells Inc
- Pfizer, Inc
- Sanofi
- Santen Pharmaceuticals
- GlaxoSmithKline plc
- Novartis AG
- Bayer AG
- Neurotech Pharmaceuticals, Inc
- Ophthotech Corporation
- F. Hoffmann-La Roche Ltd
- StemCells Inc
- Pfizer, Inc
- Sanofi
- Santen Pharmaceuticals
Get the Latest COVID-19 Analysis on this market
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak To Analyst
Pricing
-
$3000
-
$4550
-
$6550
-
$8550
-
GET FREE SAMPLE PDF
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.
Inquire for Discount